|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2020
gptkb:vaccine
|
|
gptkbp:atccode
|
J05 AE04
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:bioavailability
|
not applicable
|
|
gptkbp:casnumber
|
1809249-37-7
|
|
gptkbp:chemical_formula
|
C27 H35 N6 O8 P
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:clinical_use
|
treatment of viral infections
|
|
gptkbp:contraindication
|
hypersensitivity to remdesivir
|
|
gptkbp:defense
|
conditional recommendation for non-severe COVID-19
recommended for severe COVID-19
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:generic_availability
|
limited
|
|
gptkbp:healthcare
|
October 22, 2020
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remdesivir
|
|
gptkbp:interacts_with
|
other antiviral drugs
CYP450 inducers
CYP450 inhibitors
hepatotoxic medications
|
|
gptkbp:invention
|
patented
|
|
gptkbp:lifespan
|
approximately 1 hour
|
|
gptkbp:marketed_as
|
gptkb:European_Union
gptkb:India
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:monitors
|
0 A0 D1 B1 D1 A
|
|
gptkbp:price
|
varies by country
|
|
gptkbp:project
|
clinical trials
|
|
gptkbp:provides_guidance_on
|
included in treatment protocols
|
|
gptkbp:research_focus
|
gptkb:Marburg_virus
gptkb:MERS-Co_V
gptkb:SARS-Co_V
gptkb:COVID-19
gptkb:Nipah_virus
gptkb:Ebola_virus
|
|
gptkbp:research_status
|
ongoing studies
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:side_effect
|
headache
nausea
diarrhea
rash
liver enzyme elevation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:target_virus
|
gptkb:SARS-Co_V-2
|
|
gptkbp:trade
|
gptkb:Veklury
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|